Showing recent highlights
What's New
PubMed · November 1, 2026
Researchers found that low doses of a protein called interleukin-2 — which helps calm an overactive immune system by boosting a type of protective immune cell — significantly reduced lupus disease activity in patients across nine clinical trials. People receiving this treatment showed measurable improvements in lupus flare scores and certain blood markers that doctors use to track how active lupus is in the body, which could matter because better disease control may help prevent organ damage over time. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · November 1, 2026
Researchers found that certain medications targeting proteins called BAFF and APRIL — which play a role in the overactive immune response seen in lupus — helped more people with lupus respond to treatment compared to a placebo, without a noticeable increase in serious side effects. One of these medications, belimumab (brand name Benlysta), showed especially consistent results across multiple studies, including in people with lupus-related kidney damage (when the immune system attacks the kidneys). This is early research and hasn't yet changed treatment guidelines.
Medications
PubMed · November 1, 2026
A study found that memantine (a medication already used for Alzheimer's disease, sold under the brand name Namenda) may help improve thinking and memory problems in people with lupus — a condition where the immune system mistakenly attacks the body. Researchers found that people with lupus who took memantine showed greater improvements in memory and mental function over 12 weeks compared to those who took a placebo (a sugar pill with no active medicine). This appears to be a new and emerging option for a problem that often persists even when lupus itself is being treated, though the study was small and more research is needed.
Ask your doctor: Ask the doctor whether memantine might help improve the patient's memory and thinking problems that are related to lupus, based on a new research study showing it could help with these symptoms.
What's New
PubMed · November 1, 2026
Researchers found that people with lupus (an autoimmune disease where the immune system mistakenly attacks the body) appear to have a significantly higher risk of developing cancers linked to HPV, the human papillomavirus — a very common virus that can cause certain cancers. The risk of cervical cancer was more than twice as high compared to the general population, but the study also flagged that cancers in other areas, like the vulva and vagina, were even more elevated, suggesting that routine screening focused only on the cervix may be missing part of the picture for people with lupus. This is early research and hasn't yet changed treatment guidelines.
Ask your doctor: Ask the doctor whether the patient with lupus should have cancer screenings beyond the regular cervical cancer screening, since the research shows that lupus increases the risk of HPV infections and other types of HPV-related cancers.
What's New
PubMed · November 1, 2026
Researchers found that statin medications — the same cholesterol-lowering drugs many people already take for heart health — may help reduce inflammation and lower cholesterol levels in people with lupus, a condition that already raises the risk of serious heart problems like heart attacks or strokes. However, the study did not find clear evidence that statins slowed the buildup of plaque in blood vessel walls, which is one of the main ways heart disease develops. This is early research and hasn't yet changed treatment guidelines.
Medications
NEJM · October 14, 2026
A study looked at a medication called obinutuzumab (also known by the brand name Gazyva) in people with active lupus — a disease where the immune system mistakenly attacks the body's own tissues. Researchers found that this treatment, which works by targeting certain immune cells thought to drive lupus, showed promising results for managing the disease. This appears to be an emerging option being explored for lupus, rather than a safety update or an existing guideline recommendation.
Ask your doctor: Ask the doctor whether the patient should know about a new drug called obinutuzumab that was studied as a treatment for active lupus.
What's New
PubMed · October 1, 2026
Researchers found that people with rheumatic diseases — conditions like rheumatoid arthritis or lupus where the immune system attacks the body — who take hydroxychloroquine (a common treatment) for many years have a small but growing risk of developing eye damage (where the medication gradually harms the retina, the light-sensitive layer at the back of the eye). The risk stayed very low in the first five years but rose to about 1 in 18 people after 15 years of use, and the risk was higher for those taking larger daily doses, women, and people with kidney disease. This matters because eye damage from this medication can sometimes be permanent, so understanding who is most at risk could help patients and their doctors have more informed conversations about monitoring. This is early research and hasn't yet changed treatment guidelines.
Ask your doctor: Ask the doctor whether the patient should have their eyes checked with special imaging to look for vision problems from taking hydroxychloroquine long-term for rheumatoid arthritis.
What's New
PubMed · October 1, 2026
A study found that rituximab — a medication that calms an overactive immune system — may help people with lupus whose kidney problems keep coming back or don't respond to other treatments. Researchers looked at 19 studies and found that roughly two out of three patients showed some improvement in kidney function, and the amount of protein leaking into their urine (a sign of kidney stress) dropped meaningfully over time. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · October 1, 2026
A study found that stigma — meaning feeling judged, embarrassed, or treated unfairly because of a health condition — is surprisingly common among people living with lupus, with nearly half reporting at least one experience of stigma or discrimination. This can affect people's personal relationships, work life, and mental health, yet researchers found that healthcare teams don't consistently ask about it during routine appointments. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · October 1, 2026
A study looked at people with lupus nephritis — a serious form of lupus that attacks the kidneys — and compared different combinations of medicines used to help put the disease into remission (meaning symptoms calm down significantly). Researchers found that adding a drug called Tacrolimus to the standard two-drug treatment led to the highest rates of kidney remission, outperforming several other add-on medications, without a worrying increase in serious side effects or infections. This could matter for people with lupus because finding the most effective combination early on may help protect the kidneys from long-term damage. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · October 1, 2026
Researchers found that a drug called baricitinib, which works by calming overactive immune signaling in the body, doesn't help all people with lupus equally — but it did show meaningful benefits for two specific subgroups of patients whose immune systems showed particular patterns of activity when analyzed at the genetic level. What makes this interesting is that these subgroups couldn't be spotted just by looking at symptoms or standard test results; only a deeper look at gene activity revealed who was likely to respond. This could eventually help doctors match the right lupus patients to this treatment, rather than using a one-size-fits-all approach — though this is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · October 1, 2026
A study found that for people with lupus, checking the level of a medication called mycophenolate (a drug that calms the immune system) in their blood may help predict whether it's actually working. Researchers found that patients whose blood levels reached a certain threshold were significantly more likely to respond well to the medication — and this was especially true for people whose lupus was affecting areas other than the kidneys, such as the skin, joints, or other organs. This is early research and hasn't yet changed treatment guidelines.
Ask your doctor: Ask the doctor whether checking the patient's mycophenolate (CellCept) drug levels in the blood might help figure out if the current dose is working well for their lupus.
What's New
NEJM · September 30, 2026
Researchers found new evidence linking NETs — tiny web-like structures released by white blood cells during infection or inflammation — to lupus, a disease where the immune system mistakenly attacks the body. These NETs may trigger or worsen the immune system's misfiring in lupus, which could help explain why some people have more severe symptoms or flares. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 23, 2026
A study found that when nurses took a lead role in supporting people with lupus — through education, mental health support, and self-management coaching — patients tended to feel better and manage their condition more effectively. Lupus is a long-term illness where the immune system mistakenly attacks the body, and it can affect many organs at once, making day-to-day life challenging. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 15, 2026
Researchers found that people with lupus — an autoimmune disease where the immune system mistakenly attacks the body — are about 2.6 times more likely to have a stroke than people without lupus, looking across 25 studies involving over 5 million individuals. This higher risk applied to both types of stroke: the kind caused by a blocked blood vessel and the kind caused by bleeding in the brain. Understanding this connection matters because it highlights stroke as a serious concern for people living with lupus, which may encourage closer monitoring of their overall health. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 11, 2026
Researchers found that a rare genetic condition called DNASE1L3 deficiency — where the body can't properly clear out DNA from dead cells, causing the immune system to stay on high alert — can cause lupus or lupus-like illness in children, but the way it shows up varies widely from person to person. Some children develop milder forms affecting blood vessels, while others experience severe lupus with serious organ damage, suggesting this genetic change causes a whole range of disease rather than just one predictable pattern. Understanding this range could eventually help doctors recognize and treat these patients earlier and more precisely. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
Researchers found that people with rheumatoid arthritis — a condition where the immune system attacks the joints, causing pain and swelling — use physical and occupational therapy at very different rates depending on where they live, with people in European countries generally receiving these services more often than those in North America. The review also found that physical therapy was used far more than occupational therapy, which helps people manage daily tasks affected by their condition. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
Researchers found that a rare lung complication of lupus called shrinking lung syndrome — where the lungs gradually become smaller and breathing becomes harder — responded well to treatment in most patients, with 75 to 95 percent experiencing symptom relief. However, only about 1 in 5 patients fully regained normal lung function, meaning most people were left with some lasting breathing difficulty. For patients who didn't respond to standard steroid treatment, a medication called rituximab (a drug that targets certain immune cells) showed promise as a next step. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
Researchers found that adding a medication called voclosporin to the usual treatment for lupus nephritis — a type of kidney damage caused by lupus — helped reduce protein in the urine much more effectively than standard treatment alone, which is a sign that the kidneys are being better protected. However, the study also found that people taking voclosporin experienced more side effects and serious medical events, raising real questions about how safely it can be used. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
Researchers found that a drug called litifilimab helped reduce skin symptoms in people with a form of lupus that mainly affects the skin — a condition that currently has no approved targeted treatments. In the study, people taking litifilimab were more likely to see noticeable skin improvement compared to those taking a placebo (an inactive treatment), with some showing results as early as four weeks in. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
Researchers found that a computerized decision-support tool designed to help people with lupus understand their treatment options was well-received — around 78% to 92% of nearly 1,900 patients rated the information as good to excellent, and 90% found it helpful for thinking through treatment choices. People especially appreciated the content and the clear layout, though some wanted even more detail about their medication options. Tools like this could make it easier for patients to feel informed and involved in conversations with their doctor about managing lupus. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
Researchers found that a new antibody treatment called A-319 helped people with lupus — an autoimmune disease where the immune system mistakenly attacks the body's own tissues — by wiping out specific immune cells (called B cells) that drive the disease. In a small early-stage study of 12 people, 8 out of 10 reached a state of low disease activity, and the treatment appeared reasonably safe, with most side effects being mild. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · August 31, 2026
Researchers found that people with lupus who also develop a lung condition called interstitial lung disease — where the lung tissue becomes scarred and inflamed over time — tended to be about 8 years older on average than lupus patients without this lung involvement. They also found that people with Raynaud phenomenon (a condition where fingers and toes turn white or blue in the cold due to reduced blood flow) were about three times more likely to have this lung complication. This could matter for someone living with lupus because it may help doctors identify who to watch more closely for lung problems — though this is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · August 18, 2026
Researchers found that in studies testing treatments for the skin symptoms of lupus — a disease where the immune system mistakenly attacks the body — patients who received a placebo (a dummy treatment with no active medicine) still showed meaningful improvement in their skin. This 'placebo response' matters because when people in the comparison group get better on their own, it makes it harder for researchers to tell whether a real treatment is actually working. Understanding how often and why this happens could help scientists design better studies and eventually find treatments that are formally approved for lupus skin disease, since none currently exist specifically for this condition. This is early research and hasn't yet changed treatment guidelines.
What's New
NEJM · August 15, 2026
Researchers found that certain medications can actually trigger a specific form of lupus that affects the skin, called subacute cutaneous lupus erythematosus — meaning the drug itself may be causing or worsening the condition rather than the underlying disease alone. This matters for people with lupus because it suggests that reviewing the medications someone is already taking could be an important piece of figuring out why their symptoms are flaring or appearing in the first place. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · August 14, 2026
Researchers found that a new type of immune cell therapy — made from umbilical cord blood and engineered to target and wipe out certain immune cells that drive lupus — helped five people with hard-to-treat lupus go into low disease activity or even full remission, with very few side effects. Unlike similar treatments that can cause serious reactions, this approach was remarkably well tolerated, with no dangerous immune overreactions or nerve-related complications. This is early research and hasn't yet changed treatment guidelines.
Guidelines
PubMed · August 4, 2026
According to the Sociedad Española de Reumatología (a major Spanish rheumatology organization) guidelines, doctors treating lupus now have three approved biological therapies — belimumab, anifrolumab, and obinutuzumab — to choose from, and these treatments are being used earlier in the course of the disease than before. Each option works somewhat differently and suits different aspects of lupus, so the choice depends on a person's specific situation, including how fast they need relief and their individual safety considerations. For people with lupus nephritis (a form of lupus that affects the kidneys), these newer therapies are now considered a first-line option because they have shown better outcomes than standard treatment alone.
Ask your doctor: Ask the doctor whether the patient might be a good candidate for belimumab, anifrolumab, or obinutuzumab, since those are newer biological treatments for lupus that have shown strong evidence of working.
What's New
PubMed · August 1, 2026
A study found that people with lupus who did high-intensity interval training — short bursts of intense exercise — three times a week for 12 weeks meaningfully improved their aerobic fitness (how well the body uses oxygen during activity) compared to those who didn't exercise. However, the training didn't significantly reduce fatigue, and researchers noticed that people with higher levels of a lupus-related immune signal called type 1 interferons seemed to benefit less from the exercise, though this finding was not conclusive. This could matter for people with lupus because it suggests structured exercise may support physical fitness, but the relationship between lupus disease activity and exercise response may be complex. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · August 1, 2026
Researchers found that two biologic medications used for lupus — belimumab and anifrolumab — both worked better than a placebo at reducing lupus symptoms, but anifrolumab showed a stronger overall response by one key measure. However, people taking anifrolumab were significantly more likely to develop a herpes zoster infection (commonly known as shingles) compared to those taking belimumab. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · August 1, 2026
Researchers found that a higher starting dose of anifrolumab — a treatment that works by calming an overactive immune signal linked to lupus — may work better for people with lupus nephritis, which is a form of kidney damage caused by lupus. The higher dose appeared to reduce protein in the urine more quickly (having too much protein in the urine is a sign that the kidneys are under stress), and patients who responded well were less likely to stop treatment early. This is early research and hasn't yet changed treatment guidelines.
For informational purposes only. Not medical advice. Always consult a physician before making any health decisions.